Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer
Our results demonstrate that disease aggressiveness can be related to reduced chromatin and gene expression dynamics. We anticipate that the resistant signature identified here using an integrative target discovery approach can be applied to complex, more representative models and validated before they can be targeted by suitable therapeutic agents.
Authors
- Aamer Ikram (ORCID: https://orcid.org/0000-0002-6440-750X)
- Atif Naeem (ORCID: https://orcid.org/0000-0001-9658-0043)
- Ateequllah Hayat (ORCID: https://orcid.org/0000-0003-0277-7668)
- Vinothini Rajeeve (ORCID: https://orcid.org/0000-0002-6361-4291)
- Najah Alsubaie (ORCID: https://orcid.org/0000-0002-6381-9019)
- J Steggall
Institutions
- St George's, University of London (GB)
- Queen Mary University of London (GB)
- Taif University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Abdullah International Medical Research Center (SA)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1038/s41416-025-03174-3
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05